Previous 10 | Next 10 |
The following slide deck was published by Morphic Holding, Inc. in conjunction with this event. For further details see: Morphic Holding (MORF) Presents At 39th Annual Healthcare Conference - Slideshow
WALTHAM, Mass. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the expansion of its research and development col...
WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39 th Annual J.P. Morgan Hea...
WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Dr. Martin W. Edwards, to its Board of Directors. Dr. Edwards is a veteran leader in the drug development indu...
WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that members of the Morphic management ...
Morphic (MORF): Q3 GAAP EPS of $0.17 beats by $0.71.Revenue of $25.76M (+353.5% Y/Y) beats by $13.46M.Press Release For further details see: Morphic EPS beats by $0.71, beats on revenue
Initiated p hase 1 clinical trial for MORF-057 with results expected by mid-2021 Presented d ata at UEG 2020 that reinforce preclinical potency and selectivity profile of MORF-057 Received $20 million from AbbVie exercising option to αv...
- Data validat e physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α 4 β 7 integrin - -MORF-057, inhibitor of α 4 β 7 integr...
First o rally available integrin inhibitor from MInT Platform to enter the clinic MORF-057, inhibitor o f α 4 β 7 integrin , in development to treat i nflammatory bowel disease Phase 1 pr...
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Nex...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 08:15:05 ET RBC Capital analyst issues SECTOR PERFORM recommendation for MORF on July 9, 2024 06:29AM ET. The previous analyst recommendation was Outperform. MORF was trading at $55.74 at issue of the analyst recommendation. The overall analyst consensus : BUY...
2024-07-08 20:00:07 ET Edward Nash from Canaccord Genuity issued a price target of $57.00 for MORF on 2024-07-08 18:49:00. The adjusted price target was set to $57.00. At the time of the announcement, MORF was trading at $55.74. The overall price target consensus is at $...